- Home
- WLK vs DVA Comparison
WLK vs DVA Comparison
Compare WLK & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLK
- DVA
- Stock Information
- Founded
- WLK 1986
- DVA 1994
- Country
- WLK United States
- DVA United States
- Employees
- WLK N/A
- DVA N/A
- Industry
- WLK Major Chemicals
- DVA Misc Health and Biotechnology Services
- Sector
- WLK Industrials
- DVA Health Care
- Exchange
- WLK Nasdaq
- DVA Nasdaq
- Market Cap
- WLK 9.2B
- DVA 10.8B
- IPO Year
- WLK 2004
- DVA 1995
- Fundamental
- Price
- WLK $85.79
- DVA $145.18
- Analyst Decision
- WLK Buy
- DVA Hold
- Analyst Count
- WLK 15
- DVA 3
- Target Price
- WLK $97.73
- DVA $159.33
- AVG Volume (30 Days)
- WLK 1.1M
- DVA 802.1K
- Earning Date
- WLK 08-05-2025
- DVA 08-05-2025
- Dividend Yield
- WLK 2.45%
- DVA N/A
- EPS Growth
- WLK 50.25
- DVA 14.90
- EPS
- WLK 3.00
- DVA 10.11
- Revenue
- WLK $12,013,000,000.00
- DVA $12,968,524,000.00
- Revenue This Year
- WLK N/A
- DVA $6.51
- Revenue Next Year
- WLK $6.63
- DVA $3.41
- P/E Ratio
- WLK $28.60
- DVA $14.36
- Revenue Growth
- WLK N/A
- DVA 5.11
- 52 Week Low
- WLK $68.55
- DVA $131.76
- 52 Week High
- WLK $153.34
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- WLK 57.58
- DVA 54.25
- Support Level
- WLK $81.12
- DVA $138.65
- Resistance Level
- WLK $88.51
- DVA $151.85
- Average True Range (ATR)
- WLK 3.03
- DVA 3.87
- MACD
- WLK 0.16
- DVA 0.36
- Stochastic Oscillator
- WLK 70.43
- DVA 49.47
About WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.